Propanc Biopharma, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities.
As of March 31, 2025, we were in default under certain loan issued to certain noteholders on October 3, 2019 for failure to pay an aggregate of $65,280 and $50,477 of principal and accrued interest, respectively, and noteholder on August 15, 2023 for failure to pay an aggregate of $132,000 and $30,711 of principal and accrued interest, respectively, as of March 31, 2025, subsequent to their maturity date. Additionally, outstanding convertible notes for total principal amount of $275,485 with maturity dates between April 2024 and March 2025 are currently in default as of March 31, 2025. We are currently in discussions with such noteholders to extend such maturity date. See “Note 5 and 6” to our unaudited condensed consolidated financial statements in Part I of this Quarterly Report for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.